Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acolbifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 20/20 | 1.00 |
| ▸ | ESR2 known ✓ | Q92731 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acolbifene SCHEMBL29351361 | 1.00 | ESR1 (1.00) | ESR1ESR2 | |
| Acolbifene SCHEMBL406183 | 1.00 | ESR1 (1.00) | ESR1ESR2 | |
| Acolbifene SCHEMBL7207561 | 1.00 | ESR1 (1.00) | ESR1ESR2 | |
| Acolbifene SCHEMBL9979094 | 0.99 | ESR1 (0.98) | ESR1ESR2 | |
| SCHEMBL15019602 | 0.99 | ESR1 (0.98) | ESR1ESR2 | |
| SCHEMBL7054458 | 0.95 | ESR1 (0.91) | ESR1ESR2 | |
| Acolbifene SCHEMBL28088521 | 0.93 | ESR1 (0.87) | ESR1ESR2 | |
| SCHEMBL4804921 | 0.93 | ESR1 (0.87) | ESR1ESR2 | |
| SCHEMBL14856500 | 0.91 | ESR1 (0.87) | ESR1ESR2 | |
| SCHEMBL7056486 | 0.91 | ESR1 (0.91) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0615448-B1 | SEX STEROID ACTIVITY INHIBITORS | ENDORECH INC (CA) | 2002-05-02 | — | — | EP | claimed |
| US-5980938-A | ADMINISTERING A DIBENZYL BENZOPYRANS | ELI LILLY AND COMPANY (US) | 1999-11-09 | — | — | US | claimed |
| JP-2784846-B2 | — | — | 1998-08-06 | — | — | JP | claimed |
| US-5446061-A | Administering 2-phenyl-3-aryl-dihydrobenzopyran derivatives | ELI LILLY AND COMPANY (US) | 1995-08-29 | — | — | US | claimed |
| EP-0652007-A1 | Use of 2-phenyl-3-aryl-dihydrobenzopyrans for inhibiting bone loss | ELI LILLY AND COMPANY (US) | 1995-05-10 | — | — | EP | claimed |
| EP-0652006-A1 | Use of 2-phenyl-3-aryl-dihychobenzopyrans for lowering serum cholesterol | ELI LILLY AND COMPANY (US) | 1995-05-10 | — | — | EP | claimed |
| US-5407947-A | Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans | ELI LILLY AND COMPANY (US) | 1995-04-18 | — | — | US | claimed |
| US-5395842-A | Inhibitors of sex steroids | ENDORECHERCHE INC. (CA) | 1995-03-07 | — | — | US | claimed |
| EP-0615448-A1 | SEX STEROID ACTIVITY INHIBITORS | ENDORECHERCHE INC. (CA) | 1994-09-21 | — | — | EP | claimed |
| WO-1993010741-A2 | SEX STEROID ACTIVITY INHIBITORS | ENDORECHERCHE INC. (CA) | 1993-06-10 | — | — | WO | claimed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| WO-2021225767-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-11-11 | — | — | WO | disclosed |
| EP-3473630-B1 | BORON-BASED PRODRUG STRATEGY FOR INCREASED BIOAVAILABILITY AND LOWER-DOSAGE REQUIREMENTS FOR DRUG MOLECULES CONTAINING AT LEAST ONE PHENOL (OR AROMATIC HYDROXYL) GROUP | XAVIER UNIV OF LOUISIANA (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3473630-A1 | BORON-BASED PRODRUG STRATEGY FOR INCREASED BIOAVAILABILITY AND LOWER-DOSAGE REQUIREMENTS FOR DRUG MOLECULES CONTAINING AT LEAST ONE PHENOL (OR AROMATIC HYDROXYL) GROUP | Xavier University Of Louisiana (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-1996026201-A1 | BENZOPYRAN-CONTAINING COMPOUNDS AND METHOD FOR THEIR USE | ENDORECHERCHE, INC. (CA) | 1996-08-29 | — | — | WO | disclosed |
| US-5446061-A | Administering 2-phenyl-3-aryl-dihydrobenzopyran derivatives | ELI LILLY AND COMPANY (US) | 1995-08-29 | — | — | US | disclosed |
| EP-0652007-A1 | Use of 2-phenyl-3-aryl-dihydrobenzopyrans for inhibiting bone loss | ELI LILLY AND COMPANY (US) | 1995-05-10 | — | — | EP | disclosed |
| EP-0652006-A1 | Use of 2-phenyl-3-aryl-dihychobenzopyrans for lowering serum cholesterol | ELI LILLY AND COMPANY (US) | 1995-05-10 | — | — | EP | disclosed |
| US-5407947-A | Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans | ELI LILLY AND COMPANY (US) | 1995-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | ESR1 3467/4885ESR2 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.